|
| 35970920 | Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. | Nat Med | 2022 |
| 30770496 | Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. | Clin Cancer Res | 2019 |
| 29415044 | A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. | PLoS Comput Biol | 2018 |
| 29751996 | Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different. | Trends Immunol | 2018 |
| 27908594 | Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. | Lancet Oncol | 2017 |
| 28794284 | Genomic profiling of ER<sup>+</sup> breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. | Sci Transl Med | 2017 |
| 28525389 | Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. | Oncotarget | 2017 |
| 27291498 | Unique genomic features in adolescent and young adult, as compared to older adult, non-Hodgkin lymphoma and potential therapeutic targets. | Br J Haematol | 2017 |
| 27363283 | Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. | Leukemia | 2017 |
| 27489863 | Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. | Oncoscience | 2016 |
| 27197177 | Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. | Cancer Res | 2016 |
| 26933124 | Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing. | Clin Cancer Res | 2016 |
| 27245569 | Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. | Oncologist | 2016 |
| 26966091 | Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. | Blood | 2016 |
| 27284958 | Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies. | Cancer | 2016 |
| 27052656 | Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. | Ann Oncol | 2016 |
| 27334835 | Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations. | Clin Cancer Res | 2016 |
| 27075627 | Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. | Sci Transl Med | 2016 |
| 27207748 | Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. | Oncology | 2016 |
| 27466356 | TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. | Mol Cancer Ther | 2016 |
| 26479420 | Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies. | Cancer | 2016 |
| 26314551 | The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. | Int J Cancer | 2016 |
| 26651075 | Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. | Cancer | 2016 |
| 26515496 | RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. | Clin Cancer Res | 2016 |
| 26500333 | Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. | J Clin Pathol | 2016 |
| 26149668 | Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. | Eur Urol | 2016 |
| 26670666 | Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations. | Oncologist | 2016 |
| 27566247 | Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers. | Oncologist | 2016 |
| 26664139 | A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. | Onco Targets Ther | 2015 |
| 25927147 | Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options. | Arch Pathol Lab Med | 2015 |
| 25886620 | Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. | BMC Cancer | 2015 |
| 25712460 | Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. | Ann Oncol | 2015 |
| 25882375 | Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. | Oncologist | 2015 |
| 25797355 | Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles. | Eur J Cancer | 2015 |
| 25546157 | RET fusion as a novel driver of medullary thyroid carcinoma. | J Clin Endocrinol Metab | 2015 |
| 25871911 | Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine. | Cancer Med | 2015 |
| 25658984 | Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy. | Blood Cancer J | 2015 |
| 25480824 | Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. | Oncologist | 2015 |
| 25680375 | Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. | Clin Cancer Res | 2015 |
| 25971938 | Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. | Cancer Discov | 2015 |
| 26563356 | Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib. | J Natl Cancer Inst | 2015 |
| 26182302 | Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. | JAMA Oncol | 2015 |
| 26336083 | Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. | Oncologist | 2015 |
| 26244165 | Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification. | Oncoscience | 2015 |
| 26370156 | RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors. | Cancer Discov | 2015 |
| 26238431 | Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. | Eur Urol | 2015 |
| 26021831 | Multiple gene aberrations and breast cancer: lessons from super-responders. | BMC Cancer | 2015 |
| 25078331 | Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies. | J Clin Pathol | 2014 |
| 25490892 | Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. | J Natl Cancer Inst | 2014 |
| 25266736 | Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. | Cancer Discov | 2014 |